Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Weaknesses
  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
UCB3.32%16 637
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
ROCHE HOLDING LTD.-5.40%211 135
MERCK AND COMPANY10.24%167 132
AMGEN8.11%137 400
NOVO NORDISK A/S2.24%112 650
SANOFI0.72%112 597
BAYER-0.50%105 172
ABBOTT LABORATORIES3.36%103 235
BRISTOL-MYERS SQUIBB COMPAN..0.93%101 934
ELI LILLY AND COMPANY2.07%94 133
GLAXOSMITHKLINE2.32%93 277
ASTRAZENECA-2.74%88 702
CELGENE CORPORATION-2.24%80 818
More Results
Financials (€)
Sales 2017 4 394 M
EBIT 2017 1 019 M
Net income 2017 667 M
Debt 2017 516 M
Yield 2017 1,77%
P/E ratio 2017 19,20
P/E ratio 2018 16,96
EV / Sales 2017 3,22x
EV / Sales 2018 2,99x
Capitalization 13 615 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart UCB
Duration : Period : Day
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Duration : Period : Week
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders